AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34569408 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive selection trial design
Number of subjects: 0
Study 34569408 — intervention group
Group type: EXPERIMENTAL
Intervention: De-escalation from inhaled corticosteroids (ICS)
Number of subjects: 0
Study 34569408 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment escalation studies
Number of subjects: 0
Study 32865102 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary habit training during hospital stay with telephonic reinforcement 10 days after discharge
Number of subjects: 109
Study 32865102 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control Group)
Number of subjects: 109
Study 32067262 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-539313 100 mg in fasted conditions
Number of subjects: 40
Study 32067262 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-539313 100 mg in fed conditions
Number of subjects: 40
Study 32067262 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-539313 (various doses 10-400 mg)
Number of subjects: 40
Study 35051949 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted Suicide Short Intervention Program (ASSIP)
Number of subjects: 239
Study 35051949 — intervention group
Group type: COMPARATOR
Intervention: Crisis Counseling (CC)
Number of subjects: 239
Study 33645911 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked colour imaging
Number of subjects: 302
Study 33645911 — intervention group
Group type: COMPARATOR
Intervention: White-light colonoscopy
Number of subjects: 302
Study 35388321 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMV-PSV-PEEP + AutoFlow
Number of subjects: 100
Study 35388321 — intervention group
Group type: COMPARATOR
Intervention: SIMV-PSV-PEEP
Number of subjects: 100
Study 35398501 — intervention group
Group type: EXPERIMENTAL
Intervention: AnluoHuaxian pill (AHP)
Number of subjects: 270
Study 35398501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 34812521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit2Thrive core intervention (self-monitoring app and Fitbit)
Number of subjects: 269
Study 34812521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit2Thrive core intervention with support calls, buddy, and text messages (on level)
Number of subjects: 269
Study 33970187 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm formula powder (PTF)
Number of subjects: 123
Study 33970187 — intervention group
Group type: COMPARATOR
Intervention: Human milk fortifier (HMF)
Number of subjects: 123
Study 32798689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 139
Study 32798689 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 139
Study 37937943 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical protocol informed by an arterial waveform contour analysis monitor
Number of subjects: 60
Study 37937943 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 32990608 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g of tomato juice
Number of subjects: 25
Study 32990608 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g of tomato
Number of subjects: 25
Study 32990608 — intervention group
Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 25
Study 33775981 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI-alone strategy
Number of subjects: 496
Study 33775981 — intervention group
Group type: COMPARATOR
Intervention: PVI-plus strategy
Number of subjects: 496
Study 32955841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatha yoga-based training program (HY)
Number of subjects: 80
Study 32955841 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 80
Study 34157925 — intervention group
Group type: EXPERIMENTAL
Intervention: HTO-arthroscopy (HTO-A)
Number of subjects: 82
Study 34157925 — intervention group
Group type: COMPARATOR
Intervention: HTO
Number of subjects: 82
Study 34346027 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP block
Number of subjects: 304
Study 34346027 — intervention group
Group type: EXPERIMENTAL
Intervention: TLIP block
Number of subjects: 304
Study 34346027 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 304
Study 35842288 — intervention group
Group type: EXPERIMENTAL
Intervention: Labtician BlephaDex (BD)
Number of subjects: 30
Study 35842288 — intervention group
Group type: EXPERIMENTAL
Intervention: OCuSOFT Oust Demodex (OD)
Number of subjects: 30
Study 35842288 — intervention group
Group type: EXPERIMENTAL
Intervention: Théa Blephademodex (BDdx)
Number of subjects: 30
Study 35842288 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐MED I‐Lid'n Lash Plus (ILL+)
Number of subjects: 30
Study 35842288 — intervention group
Group type: EXPERIMENTAL
Intervention: Chrissanthe Eye Cleanse (EC)
Number of subjects: 30
Study 34491340 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment for T2DM plus training in diaphragmatic breathing and systematic relaxation for 6 months
Number of subjects: 100
Study 34491340 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for T2DM
Number of subjects: 100
Study 36522207 — intervention group
Group type: EXPERIMENTAL
Intervention: European regimen (group 1): vincristine, ifosfamide, doxorubicin, and etoposide induction, and consolidation using vincristine, actinomycin D, with ifosfamide or cyclophosphamide, or busulfan and melphalan.
Number of subjects: 640
Study 36522207 — intervention group
Group type: COMPARATOR
Intervention: US regimen (group 2): vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide induction, plus ifosfamide and etoposide, and consolidation using vincristine and cyclophosphamide, or vincristine, actinomycin D, and ifosfamide, with busulfan and melphalan.
Number of subjects: 640
Study 36522207 — intervention group
Group type: EXPERIMENTAL
Intervention: European regimen (group 1)
Number of subjects: 640
Study 36522207 — intervention group
Group type: COMPARATOR
Intervention: US regimen (group 2)
Number of subjects: 640
Study 33522444 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal management training
Number of subjects: 0
Study 33522444 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions
Number of subjects: 0
Study 33522444 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study 35586621 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-Virgin Olive Oil + Traditional Brazilian Diet (OliveOil+DietBra)
Number of subjects: 40
Study 35586621 — intervention group
Group type: COMPARATOR
Intervention: Extra-Virgin Olive Oil only
Number of subjects: 40
Study 34925655 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning module
Number of subjects: 201
Study 34925655 — intervention group
Group type: COMPARATOR
Intervention: Small-group lecture
Number of subjects: 201
Study 35605902 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS before motor practice (tDCSbefore)
Number of subjects: 100
Study 35605902 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS during motor practice (tDCSduring)
Number of subjects: 100
Study 35605902 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS after motor practice (tDCSafter)
Number of subjects: 100
Study 35605902 — intervention group
Group type: COMPARATOR
Intervention: Control group with motor practice (CONmp)
Number of subjects: 100
Study 35605902 — intervention group
Group type: COMPARATOR
Intervention: Control group without motor practice (CON)
Number of subjects: 100
Study 33604735 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral (CL) ACLR using semitendinosus (ST) graft from the contralateral leg
Number of subjects: 140
Study 33604735 — intervention group
Group type: COMPARATOR
Intervention: Ipsilateral (IL) ACLR using semitendinosus (ST) graft from the ipsilateral leg
Number of subjects: 140
Study 33864164 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Cancer Recurrence instrument (BreastCaRe)
Number of subjects: 1170
Study 32453913 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (120 mg for 4 days)
Number of subjects: 10
Study 32453913 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (300 mg for 7 days)
Number of subjects: 10
Study 36413385 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week internet-delivered mindfulness-based cancer recovery (iMBCR) program
Number of subjects: 103
Study 36413385 — intervention group
Group type: COMPARATOR
Intervention: usual care and 4-week program of health education information (control group)
Number of subjects: 103
Study 35312441 — intervention group
Group type: EXPERIMENTAL
Intervention: IM20 × 4
Number of subjects: 0
Study 35312441 — intervention group
Group type: EXPERIMENTAL
Intervention: IM60 × 4
Number of subjects: 0
Study 35312441 — intervention group
Group type: COMPARATOR
Intervention: IM20 × 3
Number of subjects: 0
Study 32487102 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab (monthly for 6 months)
Number of subjects: 162
Study 36397217 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture+rTMS combination group
Number of subjects: 90
Study 36397217 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS combination group
Number of subjects: 90
Study 36397217 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (escitalopram oxalate)
Number of subjects: 90
Study 32895196 — intervention group
Group type: EXPERIMENTAL
Intervention: LTD4-BPT
Number of subjects: 151
Study 32895196 — intervention group
Group type: COMPARATOR
Intervention: MCH-BPT
Number of subjects: 151
Study 35090162 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 18
Study 35090162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 18
Study 35090162 — intervention group
Group type: COMPARATOR
Intervention: Cerebral transit time
Number of subjects: 18
Study 33632189 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal block (RIB) with 20-mL 0.375% ropivacaine
Number of subjects: 90
Study 33632189 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal block with sub-serratus plane block (RISS) using a total of 40-mL 0.375% ropivacaine
Number of subjects: 90
Study 33632189 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - no block intervention
Number of subjects: 90
Study 32804661 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cultured epidermal cells
Number of subjects: 0
Study 32804661 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cultured autologous skin cell suspensions
Number of subjects: 0
Study 32804661 — intervention group
Group type: COMPARATOR
Intervention: Split-thickness skin autografts (STSGs)
Number of subjects: 0
Study 33837571 — intervention group
Group type: EXPERIMENTAL
Intervention: PMS50 supplementation (550 mg/day)
Number of subjects: 50
Study 33837571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 34426527 — intervention group
Group type: EXPERIMENTAL
Intervention: MEEi <0.34 mL/s per gram
Number of subjects: 1703
Study 34426527 — intervention group
Group type: EXPERIMENTAL
Intervention: MEEi
Number of subjects: 1703
Study 35140339 — intervention group
Group type: EXPERIMENTAL
Intervention: Two courses of DCF (docetaxel 70 mg/m2, cisplatin 70 mg/m2 i.v. on day 1, fluorouracil 700 mg/m2 continuous infusion for 5 days) every 3 weeks
Number of subjects: 180
Study 35140339 — intervention group
Group type: COMPARATOR
Intervention: Three courses of DCF (docetaxel 70 mg/m2, cisplatin 70 mg/m2 i.v. on day 1, fluorouracil 700 mg/m2 continuous infusion for 5 days) every 3 weeks
Number of subjects: 180
Study 34308314 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2400 mg/day for 12 weeks
Number of subjects: 153
Study 34308314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 34308314 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 153
Study 35164698 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training (n=20), 40 min/session, at least 4 times/week for 12 weeks, with protein supplementation (9 g/day).
Number of subjects: 40
Study 35164698 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20), received exercise instruction without active encouragement and continuous monitoring, with protein supplementation (9 g/day).
Number of subjects: 40
Study 32674235 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation combined with enteral nutrition (EN group)
Number of subjects: 150
Study 32674235 — intervention group
Group type: COMPARATOR
Intervention: Conventional nutrition (Con group)
Number of subjects: 150
Study 33025835 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents as Teachers with Smart Parents‐Safe and Healthy Kids (PAT+SPSHK)
Number of subjects: 0
Study 33025835 — intervention group
Group type: COMPARATOR
Intervention: Parents as Teachers as usual (PAT‐AU)
Number of subjects: 0
Study 34646753 — intervention group
Group type: EXPERIMENTAL
Intervention: Online psychological intervention (8 modules based on motivational interviewing and cognitive-behavioral therapy, with weekly therapeutic support via phone calls lasting a maximum of 10 minutes)
Number of subjects: 134
Study 34646753 — intervention group
Group type: EXPERIMENTAL
Intervention: Online psychological intervention
Number of subjects: 134
Study 34646753 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 134
Study 36114133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioneuroablation (CNA)
Number of subjects: 48
Study 36114133 — intervention group
Group type: COMPARATOR
Intervention: Optimal nonpharmacologic therapy (Control)
Number of subjects: 48
Study 33559439 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with ibuprofen sustained‐release capsule
Number of subjects: 144
Study 33559439 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen sustained‐release capsule
Number of subjects: 144
Study 35257652 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network-based supportive program (WhatsApp)
Number of subjects: 60
Study 35257652 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 33568703 — intervention group
Group type: EXPERIMENTAL
Intervention: Charged DNA rods at low ionic strengths (below 1-2 mM salt)
Number of subjects: 0
Study 33568703 — intervention group
Group type: EXPERIMENTAL
Intervention: Various experimental methods (image-time correlation, microscopic dynamics in small angle dynamic light scattering, optical activity in second harmonic generation, differential scanning calorimetry)
Number of subjects: 0
Study 33568703 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiral pitches of the N* phase
Number of subjects: 0
Study 32568651 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 mg of intravenous theophylline
Number of subjects: 0
Study 32568651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35292925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (oral liquid formulation 0.5 mg bid)
Number of subjects: 211
Study 35292925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 33682043 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal innocuous stimuli
Number of subjects: 19
Study 33682043 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal noxious stimuli
Number of subjects: 19
Study 33682043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical innocuous stimuli
Number of subjects: 19
Study 33682043 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical noxious stimuli
Number of subjects: 19
Study 32352368 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension formulation (test)
Number of subjects: 0
Study 32352368 — intervention group
Group type: COMPARATOR
Intervention: Granule formulation (reference)
Number of subjects: 0
Study 35078446 — intervention group
Group type: EXPERIMENTAL
Intervention: SOAR knee health program (exercise-based program)
Number of subjects: 70
Study 34890212 — intervention group
Group type: COMPARATOR
Intervention: Intensive chemotherapy
Number of subjects: 4482
Study 34890212 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission (CR)
Number of subjects: 4482
Study 33766922 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI of culprit and non-culprit lesions
Number of subjects: 0
Study 33766922 — intervention group
Group type: COMPARATOR
Intervention: Culprit lesion-only PCI
Number of subjects: 0
Study 32719263 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral approach of GNB with 4 mL of 0.5% bupivacaine and 40 mg of triamcinolonacetonide
Number of subjects: 50
Study 32719263 — intervention group
Group type: COMPARATOR
Intervention: Intraoral approach of GNB with 4 mL of 0.5% bupivacaine and 40 mg of triamcinolonacetonide
Number of subjects: 50
Study 34302609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone spray + oral betamethasone (0.1 mg/kg per day for 7 days)
Number of subjects: 28
Study 34302609 — intervention group
Group type: COMPARATOR
Intervention: Intranasal beclomethasone spray only
Number of subjects: 28
Study 33392871 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv in heart failure with reduced ejection fraction (GALACTIC-HF)
Number of subjects: 0
Study 33392871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin in patients with diabetes and recent heart failure exacerbation
Number of subjects: 0
Study 33392871 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia (STRENGTH)
Number of subjects: 0
Study 33392871 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids in elderly patients with recent myocardial infarction (OMEMI)
Number of subjects: 0
Study 33392871 — intervention group
Group type: EXPERIMENTAL
Intervention: Evinacumab in patients with refractory hypercholesterolemia
Number of subjects: 0
Study 33392871 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography for assessment of suspected acute coronary syndrome
Number of subjects: 0
Study 33392871 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill for primary prevention of cardiovascular disease in intermediate-risk people (International Polycaps Study - TIPS-3)
Number of subjects: 0
Study 33392871 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMSON trial - three-arm-N-of-1 trial for patient nonadherence to statin therapy
Number of subjects: 0
Study 35370766 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT; n = 7)
Number of subjects: 24
Study 35370766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor Training (SMT; n = 10)
Number of subjects: 24
Study 35370766 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG; n = 7)
Number of subjects: 24
Study 32519140 — intervention group
Group type: EXPERIMENTAL
Intervention: IBGard™
Number of subjects: 0
Study 32519140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34988975 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% 5-fluorouracil (5-FU)
Number of subjects: 40
Study 34988975 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% imiquimod (IMIQ)
Number of subjects: 40
Study 34988975 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen (sun-protective factor 30+)
Number of subjects: 40
Study 33555418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin (rosuvastatin 20 mg daily × 14 days)
Number of subjects: 310
Study 33555418 — intervention group
Group type: COMPARATOR
Intervention: Control (rosuvastatin 5 mg daily × 14 days)
Number of subjects: 310
Study 33555418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin
Number of subjects: 310
Study 33555418 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 310
Study 32830164 — intervention group
Group type: EXPERIMENTAL
Intervention: AWL treated with resin infiltration
Number of subjects: 50
Study 32830164 — intervention group
Group type: EXPERIMENTAL
Intervention: AWL treated with resin infiltration and 5,000 cycles of thermocycling
Number of subjects: 50
Study 32830164 — intervention group
Group type: EXPERIMENTAL
Intervention: AWL treated with resin infiltration and 10,000 cycles of thermocycling
Number of subjects: 50
Study 32830164 — intervention group
Group type: COMPARATOR
Intervention: AWL with no treatment
Number of subjects: 50
Study 32830164 — intervention group
Group type: COMPARATOR
Intervention: Sound teeth (Group 1)
Number of subjects: 50
Study 35746502 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine administered simultaneously with other vaccines
Number of subjects: 1080
Study 35746502 — intervention group
Group type: COMPARATOR
Intervention: EV71 vaccine separate administration group
Number of subjects: 1080
Study 35746502 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (simultaneous and separate administration)
Number of subjects: 1080
Study 33144512 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Early Mobilization (VEM)
Number of subjects: 2104
Study 33144512 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 2104
Study 34343599 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily
Number of subjects: 595
Study 34343599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 595
Study 34509800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 26004
Study 35237159 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunpi Qufeng Chushi formula (YQCF)
Number of subjects: 390
Study 35237159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 32525743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet score and Alternative Healthy Eating Index
Number of subjects: 9724
Study 32525743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 9724
Study 35597443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no disinfection)
Number of subjects: 100
Study 35597443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated water (O3)
Number of subjects: 100
Study 35597443 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose Bengal (RB)
Number of subjects: 100
Study 35597443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ti-sapphire laser
Number of subjects: 100
Study 35597443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium Hexafluorosilicate (NH4)2[SiF6]
Number of subjects: 100
Study 33818780 — intervention group
Group type: EXPERIMENTAL
Intervention: ubrogepant 100 mg before erenumab 140 mg
Number of subjects: 40